Cogent Biosciences, Inc.
COGT
$4.98
$0.265.51%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -5.98% | 3.83% | -19.82% | -1.03% | -7.33% |
Total Depreciation and Amortization | 2.71% | 1.00% | 1.57% | 1.31% | 34.26% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 22.79% | 77.32% | -66.98% | 57.47% | 75.49% |
Change in Net Operating Assets | -316.98% | -108.44% | 419.99% | 179.41% | -165.61% |
Cash from Operations | -9.80% | -16.53% | -21.74% | 18.71% | -19.19% |
Capital Expenditure | -629.33% | 73.21% | -89.19% | -111.43% | 77.78% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 13.25% | 2.12% | 171.58% | -7,683.21% | -89.69% |
Cash from Investing | 12.50% | 2.47% | 171.12% | -8,205.84% | -90.05% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 19,717.46% | -79.81% | -94.50% | -94.70% | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | 100.00% | -- | -- |
Cash from Financing | 95,938.46% | -95.83% | 343.75% | -100.12% | -- |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 2,385.54% | -87.31% | 106.92% | -178.48% | 584.12% |